[Oral calcimimetics on secondary hyperparathyroidism of uremia.]
Secondary hyperparathyroidism of uremia is associated with poor health outcomes, including all-cause mortality, cardiovascular mortality, and fractures. Standard therapy for secondary hyperparathyroidism includes vitamin D receptor activators, and phosphate binders. Persistently elevated parathyroid hormone(PTH)levels may require the addition of calcimimetics which sensitizes calcium-sensing receptors on the parathyroid glands.
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Japan.
Yasuo
Y
Imanishi
D000284:Administration, Oral; D057966:Calcimimetic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000378:metabolism; D014511:Uremia
D057966:Calcimimetic Agents; D010281:Parathyroid Hormone; D002118:Calcium